Rectiv FDA Approval History
FDA Approved: Yes (First approved June 21, 2011)
Brand name: Rectiv
Generic name: nitroglycerin
Dosage form: Ointment
Company: Allergan plc
Treatment for: Anal Fissure and Fistula
Rectiv (nitroglycerin) is a topical ointment for the treatment of moderate to severe pain associated with chronic anal fissures.
Development timeline for Rectiv
| Date | Article |
|---|
| Jun 22, 2011 | Approval ProStrakan Receives FDA Approval for Rectiv for the Treatment of Moderate to Severe Pain Associated With Chronic Anal Fissures |
| Jul 10, 2006 | FDA Issues Approvable Letter to Cellegy Pharmaceuticals for Cellegesic |
| Jan 9, 2006 | Cellegy Reports Review by Advisory Committee April 2006 |
| Jun 30, 2005 | Cellegy Reports Status of Response Date for FDA Review |
| May 5, 2005 | Cellegy Reports New FDA Target Response Date of June 15 |
| Apr 18, 2005 | Cellegy Responds to FDA Inquiries Concerning Cellegesic |
| Dec 23, 2004 | FDA Issues Not Approvable Letter for Cellegesic |
| Oct 14, 2004 | Cellegesic Granted Priority Review by FDA |
| Sep 1, 2004 | NDA for Cellegesic is Accepted for Review by FDA |
| Jun 30, 2004 | Cellegy Submits NDA for Cellegesic to Treat Chronic Anal Fissure Pain |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
